DOCSLIB.ORG

RUNX1, a Transcription Factor Mutated in Breast Cancer

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
RUNX1, a Transcription Factor Mutated in Breast Cancer 1 RUNX1, a transcription factor mutated in breast cancer, 2 controls the fate of ER-positive mammary luminal cells 3 1,2 1,2,3,* 1,2,* 1,2,4 4 Maaike P.A. van Bragt , Xin Hu , Ying Xie , and Zhe Li 5 6 7 8 1 9 Division of Genetics, Brigham and Women's Hospital, Boston, Massachusetts 02115, 10 USA 2 11 Department of Medicine, Harvard Medical School, Boston, Massachusetts 02115, USA 3 12 School of Life Sciences, Jilin University, Changchun 130012, China 13 14 4 15 Corresponding author (E-mail: [email protected]) 16 *Equal contributions 17 18 Competing interests statement: The authors declare no competing interests 19 20 21 1 22 Abstract 23 RUNX1 encodes a RUNX family transcription factor (TF) and was recently identified as a 24 novel mutated gene in human luminal breast cancers. We found that Runx1 is expressed 25 in all subpopulations of murine mammary epithelial cells (MECs) except the secretory 26 alveolar luminal cells. Conditional knockout of Runx1 in MECs by MMTV-Cre led to a 27 decrease in luminal MECs, largely due to a profound reduction in the estrogen receptor 28 (ER)-positive mature luminal subpopulation, a phenotype that could be rescued by loss of 29 either Trp53 or Rb1. Mechanistically RUNX1 represses Elf5, a master regulatory TF gene 30 for alveolar cells, and regulates mature luminal TF/co-factor genes (e.g., Foxa1 and 31 Cited1) involved in the ER program. Collectively, our data identified a key regulator of the + + 32 ER luminal lineage whose disruption may contribute to development of ER luminal 33 breast cancer when under the background of either TP53 or RB1 loss. 34 2 35 Introduction 36 RUNX1, RUNX2 and RUNX3, and their common non-DNA-binding partner protein CBFβ, 37 form a small family of heterodimeric transcription factors (TFs) referred to as Core- 38 Binding Factors (CBFs) (Speck and Gilliland, 2002). They are best known as master 39 regulators of cell fate determination in blood, bone and neuron, respectively (Chuang et 40 al., 2013). RUNX1 is a master regulator of hematopoietic stem cells and multiple mature 41 blood lineages. Translocations and mutations involving both RUNX1 and CBFB are 42 frequently found in human leukemias (Speck and Gilliland, 2002). Recently, key roles of 43 this family of TFs in epithelial cells and solid tumors also started to emerge (Chuang et 44 al., 2013; Scheitz and Tumbar, 2013; Taniuchi et al., 2012). In particular, in breast 45 cancer, recent whole-genome and whole-exome sequencing studies have consistently 46 identified point mutations and deletions of RUNX1 in human luminal breast cancers 47 (Banerji et al., 2012; Ellis et al., 2012; Network, 2012). In addition, mutations in CBFB 48 were also identified in luminal breast cancers from these studies. Its gene product CBFβ 49 is critical for enhancing DNA binding by RUNX TFs through allosteric regulation (Bravo et 50 al., 2001; Tahirov et al., 2001). Thus, we hypothesized that RUNX1, together with CBFβ, 51 might play a key role in mammary epithelial cell (MEC) lineage determination as a master 52 regulatory TF, and that loss of this normal function might contribute to breast cancer 53 development. 54 There are two major epithelial cell lineages in the mammary gland (MG), luminal 55 lineage (including ductal and alveolar luminal cells) and basal lineage (the mature cell 56 type in the basal lineage is myoepithelial cell) (Figure 1A). These two types of MECs are 57 produced by multipotent mammary stem cells (MaSCs, which are basal cells) during 58 embryonic development or upon MEC transplantation to cleared mammary fat pads 59 (Shackleton et al., 2006; Spike et al., 2012; Stingl et al., 2006), but in adult MGs they 3 60 appear to be maintained largely by their distinct lineage-specific stem cells, based on 61 lineage tracing studies (Tao et al., 2014; Van Keymeulen et al., 2011). The gene 62 regulatory network that must be in place to orchestrate lineage specification and 63 differentiation of stem cells into mature MEC types remains largely elusive, although a 64 number of key TFs have been identified in recent years, e.g., GATA3 has been shown as 65 a master regulator for both ductal and alveolar luminal cells (Asselin-Labat et al., 2007; 66 Kouros-Mehr et al., 2006); ELF5 was identified as a master regulator of alveolar cells 67 (Choi et al., 2009; Oakes et al., 2008); SLUG (SNAIL2) was shown as a master regulator 68 of MaSCs, and it could reprogram differentiated MECs to transplantable MaSCs, together 69 with another TF, SOX9 (Guo et al., 2012). In this work, we asked whether RUNX1 is an 70 integral part of this transcription network and how its mutations contribute to breast 71 tumorigenesis. By using genetic, cellular and molecular approaches, we found that 72 RUNX1 is a key regulator of estrogen receptor (ER)-positive mature ductal luminal cells, + 73 and that loss of RUNX1 may contribute to development of ER luminal breast cancer 74 when under the background of either TP53 or RB1 loss. 75 Results 76 Runx1 is expressed in all MEC subsets except in alveolar luminal cells 77 We first measured expression levels of all three Runx genes and their common co-factor - + hi 78 gene Cbfb in freshly sorted basal epithelial cells (Lin CD24 CD29 ) and luminal epithelial - + lo 79 cells (Lin CD24 CD29 ) (Figure 1A) from adult virgin female mice by quantitative RT-PCR 80 (qRT-PCR). Results showed that Runx1 is the predominantly expressed Runx gene in 81 both luminal and basal cells (Figure 1B). Immunohistochemical (IHC) staining further 82 confirmed expression of RUNX1 protein in these two major MEC types in adult virgin 83 MGs (Figure 1C). However, RUNX1 expression is largely absent in alveolar luminal cells 4 84 (ALs) that start to emerge during pregnancy (Figure 1D-E). In the lactating gland, the only 85 MEC type that still expresses RUNX1 is the myoepithelial cell (Figure 1F-G). Upon 86 involution, RUNX1 expression is restored to a pattern resembling that of the virgin gland 87 (Figure 1H). Additionally, we performed microarray expression profiling of sorted subsets - + hi - 88 of MECs, including basal cells (Lin CD24 CD29 ), luminal progenitors (LPs, Lin + lo + - + lo - 89 CD24 CD29 CD61 ), mature luminal cells (MLs, Lin CD24 CD29 CD61 , mainly 90 represent ductal luminal cells in virgin MGs), and alveolar luminal cells [ALs, i.e., MECs 91 genetically marked by Wap-Cre at mid-gestation; Wap-Cre is a transgenic mouse line 92 with Cre expression under the control of the Whey acidic protein (Wap) promoter, a milk 93 protein promoter (Wagner et al., 1997)]. Estimation of Runx1 levels based on this 94 microarray data set confirmed its expression in all MEC subsets except in ALs (Figure 1I). 95 We examined Runx1 expression levels in different subsets of MECs in several additional 96 published microarray datasets (Asselin-Labat et al., 2010; Lim et al., 2010; Meier-Abt et 97 al., 2013) and further confirmed this expression pattern (Figure 1-figure supplement 1A- 98 C); in particular, in the pregnant MGs, Runx1 was also found expressed in basal MECs, 99 but not in luminal MECs (mainly ALs) (Figure 1-figure supplement 1C). Lastly, by qRT- 100 PCR, we verified that Runx1 was indeed expressed in sorted LPs and MLs, but not in 101 Wap-Cre-marked ALs (Figure 1J). 102 103 Loss of Runx1 in MECs affects multiple MEC subsets 104 The RUNX1 mutations identified from the recent sequencing studies of human breast 105 cancers include point mutations, frame-shift mutations and deletions (Banerji et al., 2012; 106 Ellis et al., 2012; Network, 2012). We analyzed the breast cancer-associated missense 107 mutations of RUNX1 to determine whether they lead to loss-of-function of RUNX1 (Figure 108 2A). Based on a previous alanine-scanning site-directed mutagenesis study (Li et al., 5 109 2003), we found that these missense mutations either affect amino acid residues in 110 RUNX1 that directly contact DNA, or disrupt the overall fold of its DNA-binding RUNT 111 domain or abolish its binding to CBFβ, both of which would also perturb its DNA-binding 112 (Figure 2B). Thus, similar to RUNX1 deletions, the point mutations also lead to loss-of- 113 function of RUNX1, due to disrupted DNA-binding ability. Therefore, we asked whether 114 and how loss of Runx1 could affect development of normal MECs. -/- 115 Runx1 mice died during mid-gestation mainly due to hemorrhages in the central 116 nervous system and are thus not suitable to determine the effect of Runx1-loss on MG 117 development (Okuda et al., 1996; Wang et al., 1996). We therefore used a conditional L/L 118 knockout allele of Runx1 (Runx1 ) (Li et al., 2006b). To facilitate characterization of 119 Runx1-null MECs, we bred in a conditional Cre-reporter, Rosa26-Stop-YFP (R26Y). 120 Cross of the floxed Runx1 mice with the R26Y reporter mice and MMTV-Cre transgenic 121 mice allowed us to simultaneously disrupt Runx1 in MECs and mark the targeted cells by 122 Yellow Fluorescent Protein (YFP) (Figure 3A). Lineage analysis revealed that in virgin 123 MGs, MMTV-Cre mainly targeted MECs in the luminal lineage, but it could also lead to 124 Cre-mediated recombination in a portion of basal MECs (Figure 3B). By fluorescence- + L/L 125 activated cell sorting (FACS), we isolated YFP MECs from MMTV-Cre;Runx1 ;R26Y L/+ and +/+ 126 females and MMTV-Cre;Runx1 ;R26Y control females and by qRT-PCR, we + L/L 127 confirmed loss of Runx1 expression in YFP MECs from MMTV-Cre;Runx1 ;R26Y L/L 128 females (Figure 3C).
Load more

Recommended publications
  • Functions of the Mineralocorticoid Receptor in the Hippocampus By
    Functions of the Mineralocorticoid Receptor in the Hippocampus by Aaron M. Rozeboom A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy (Cellular and Molecular Biology) in The University of Michigan 2008 Doctoral Committee: Professor Audrey F. Seasholtz, Chair Professor Elizabeth A. Young Professor Ronald Jay Koenig Associate Professor Gary D. Hammer Assistant Professor Jorge A. Iniguez-Lluhi Acknowledgements There are more people than I can possibly name here that I need to thank who have helped me throughout the process of writing this thesis. The first and foremost person on this list is my mentor, Audrey Seasholtz. Between working in her laboratory as a research assistant and continuing my training as a graduate student, I spent 9 years in Audrey’s laboratory and it would be no exaggeration to say that almost everything I have learned regarding scientific research has come from her. Audrey’s boundless enthusiasm, great patience, and eager desire to teach students has made my time in her laboratory a richly rewarding experience. I cannot speak of Audrey’s laboratory without also including all the past and present members, many of whom were/are not just lab-mates but also good friends. I also need to thank all the members of my committee, an amazing group of people whose scientific prowess combined with their open-mindedness allowed me to explore a wide variety of interests while maintaining intense scientific rigor. Outside of Audrey’s laboratory, there have been many people in Ann Arbor without whom I would most assuredly have gone crazy.
    [Show full text]
  • In Vivo Studies Using the Classical Mouse Diversity Panel
    The Mouse Diversity Panel Predicts Clinical Drug Toxicity Risk Where Classical Models Fail Alison Harrill, Ph.D The Hamner-UNC Institute for Drug Safety Sciences 0 The Importance of Predicting Clinical Adverse Drug Reactions (ADR) Figure: Cath O’Driscoll Nature Publishing 2004 Risk ID PGx Testing 1 People Respond Differently to Drugs Pharmacogenetic Markers Identified by Genome-Wide Association Drug Adverse Drug Risk Allele Reaction (ADR) Abacavir Hypersensitivity HLA-B*5701 Flucloxacillin Hepatotoxicity Allopurinol Cutaneous ADR HLA-B*5801 Carbamazepine Stevens-Johnson HLA-B*1502 Syndrome Augmentin Hepatotoxicity DRB1*1501 Ximelagatran Hepatotoxicity DRB1*0701 Ticlopidine Hepatotoxicity HLA-A*3303 Average preclinical populations and human hepatocytes lack the diversity to detect incidence of adverse events that occur only in 1/10,000 people. Current Rodent Models of Risk Assessment The Challenge “At a time of extraordinary scientific progress, methods have hardly changed in several decades ([FDA] 2004)… Toxicologists face a major challenge in the twenty-first century. They need to embrace the new “omics” techniques and ensure that they are using the most appropriate animals if their discipline is to become a more effective tool in drug development.” -Dr. Michael Festing Quantitative geneticist Toxicol Pathol. 2010;38(5):681-90 Rodent Models as a Strategy for Hazard Characterization and Pharmacogenetics Genetically defined rodent models may provide ability to: 1. Improve preclinical prediction of drugs that carry a human safety risk 2.
    [Show full text]
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
    [Show full text]
  • And EZH2-Regulated Gene, Has Differential Roles in AR-Dependent and -Independent Prostate Cancer
    www.impactjournals.com/oncotarget/ Oncotarget, Vol. 6, No.4 RUNX1, an androgen- and EZH2-regulated gene, has differential roles in AR-dependent and -independent prostate cancer Ken-ichi Takayama1,2, Takashi Suzuki3, Shuichi Tsutsumi4, Tetsuya Fujimura5, Tomohiko Urano1,2, Satoru Takahashi6, Yukio Homma5, Hiroyuki Aburatani4 and Satoshi Inoue1,2,7 1 Department of Anti-Aging Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan 2 Department of Geriatric Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan 3 Department of Pathology, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan 4 Genome Science Division, Research Center for Advanced Science and Technology (RCAST), The University of Tokyo, Meguro-ku, Tokyo, Japan 5 Department of Urology, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan 6 Department of Urology, Nihon University School of Medicine, Itabashi-ku, Tokyo, Japan 7 Division of Gene Regulation and Signal Transduction, Research Center for Genomic Medicine, Saitama Medical University, Hidaka, Saitama, Japan Correspondence to: Satoshi Inoue, email: [email protected] Keywords: RUNX1, androgen receptor, EZH2, prostate cancer Received: October 02, 2014 Accepted: December 09, 2014 Published: December 10, 2014 This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. ABSTRACT Androgen receptor (AR) signaling is essential for the development of prostate cancer. Here, we report that runt-related transcription factor (RUNX1) could be a key molecule for the androgen-dependence of prostate cancer. We found RUNX1 is a target of AR and regulated positively by androgen.
    [Show full text]
  • 1714 Gene Comprehensive Cancer Panel Enriched for Clinically Actionable Genes with Additional Biologically Relevant Genes 400-500X Average Coverage on Tumor
    xO GENE PANEL 1714 gene comprehensive cancer panel enriched for clinically actionable genes with additional biologically relevant genes 400-500x average coverage on tumor Genes A-C Genes D-F Genes G-I Genes J-L AATK ATAD2B BTG1 CDH7 CREM DACH1 EPHA1 FES G6PC3 HGF IL18RAP JADE1 LMO1 ABCA1 ATF1 BTG2 CDK1 CRHR1 DACH2 EPHA2 FEV G6PD HIF1A IL1R1 JAK1 LMO2 ABCB1 ATM BTG3 CDK10 CRK DAXX EPHA3 FGF1 GAB1 HIF1AN IL1R2 JAK2 LMO7 ABCB11 ATR BTK CDK11A CRKL DBH EPHA4 FGF10 GAB2 HIST1H1E IL1RAP JAK3 LMTK2 ABCB4 ATRX BTRC CDK11B CRLF2 DCC EPHA5 FGF11 GABPA HIST1H3B IL20RA JARID2 LMTK3 ABCC1 AURKA BUB1 CDK12 CRTC1 DCUN1D1 EPHA6 FGF12 GALNT12 HIST1H4E IL20RB JAZF1 LPHN2 ABCC2 AURKB BUB1B CDK13 CRTC2 DCUN1D2 EPHA7 FGF13 GATA1 HLA-A IL21R JMJD1C LPHN3 ABCG1 AURKC BUB3 CDK14 CRTC3 DDB2 EPHA8 FGF14 GATA2 HLA-B IL22RA1 JMJD4 LPP ABCG2 AXIN1 C11orf30 CDK15 CSF1 DDIT3 EPHB1 FGF16 GATA3 HLF IL22RA2 JMJD6 LRP1B ABI1 AXIN2 CACNA1C CDK16 CSF1R DDR1 EPHB2 FGF17 GATA5 HLTF IL23R JMJD7 LRP5 ABL1 AXL CACNA1S CDK17 CSF2RA DDR2 EPHB3 FGF18 GATA6 HMGA1 IL2RA JMJD8 LRP6 ABL2 B2M CACNB2 CDK18 CSF2RB DDX3X EPHB4 FGF19 GDNF HMGA2 IL2RB JUN LRRK2 ACE BABAM1 CADM2 CDK19 CSF3R DDX5 EPHB6 FGF2 GFI1 HMGCR IL2RG JUNB LSM1 ACSL6 BACH1 CALR CDK2 CSK DDX6 EPOR FGF20 GFI1B HNF1A IL3 JUND LTK ACTA2 BACH2 CAMTA1 CDK20 CSNK1D DEK ERBB2 FGF21 GFRA4 HNF1B IL3RA JUP LYL1 ACTC1 BAG4 CAPRIN2 CDK3 CSNK1E DHFR ERBB3 FGF22 GGCX HNRNPA3 IL4R KAT2A LYN ACVR1 BAI3 CARD10 CDK4 CTCF DHH ERBB4 FGF23 GHR HOXA10 IL5RA KAT2B LZTR1 ACVR1B BAP1 CARD11 CDK5 CTCFL DIAPH1 ERCC1 FGF3 GID4 HOXA11 IL6R KAT5 ACVR2A
    [Show full text]
  • MSX2 Safeguards Syncytiotrophoblast Fate of Human Trophoblast Stem Cells
    bioRxiv preprint doi: https://doi.org/10.1101/2021.02.03.429538; this version posted February 3, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. MSX2 safeguards syncytiotrophoblast fate of human trophoblast stem cells Ruth Hornbachner1, Andreas Lackner1, Sandra Haider2, Martin Knöfler2, Karl Mechtler3, Paulina A. Latos1* 1Center for Anatomy and Cell Biology, Medical University of Vienna, Austria 2Department of Obstetrics and Gynaecology, Reproductive Biology Unit, Medical University of Vienna, Austria 3Institute of Molecular Pathology, Vienna, Austria Short title: MSX2 in hTSCs Key words: human trophoblast stem cells, MSX2, syncytiotrophoblast, cytotrophoblast, SWI/SNF complex *correspondence: Paulina A. Latos, Center for Anatomy and Cell Biology, Medical University of Vienna, Schwarzspanierstrasse 17, 1090 Vienna, Austria; phone: 0043-1-40160-37718; e-mail: [email protected] 1 bioRxiv preprint doi: https://doi.org/10.1101/2021.02.03.429538; this version posted February 3, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Abstract The majority of placental pathologies are associated with failures in trophoblast differentiation, yet the underlying transcriptional regulation is poorly understood. Here, we use human trophoblast stem cells to elucidate the function of the transcription factor MSX2 in trophoblast specification.
    [Show full text]
  • Mutational Landscape and Clinical Outcome of Patients with De Novo Acute Myeloid Leukemia and Rearrangements Involving 11Q23/KMT2A
    Mutational landscape and clinical outcome of patients with de novo acute myeloid leukemia and rearrangements involving 11q23/KMT2A Marius Billa,1,2, Krzysztof Mrózeka,1,2, Jessica Kohlschmidta,b, Ann-Kathrin Eisfelda,c, Christopher J. Walkera, Deedra Nicoleta,b, Dimitrios Papaioannoua, James S. Blachlya,c, Shelley Orwicka,c, Andrew J. Carrolld, Jonathan E. Kolitze, Bayard L. Powellf, Richard M. Stoneg, Albert de la Chapelleh,i,2, John C. Byrda,c, and Clara D. Bloomfielda,c aThe Ohio State University Comprehensive Cancer Center, Columbus, OH 43210; bAlliance for Clinical Trials in Oncology Statistics and Data Center, The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210; cDivision of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210; dDepartment of Genetics, University of Alabama at Birmingham, Birmingham, AL 35294; eNorthwell Health Cancer Institute, Zucker School of Medicine at Hofstra/Northwell, Lake Success, NY 11042; fDepartment of Internal Medicine, Section on Hematology & Oncology, Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, NC 27157; gDepartment of Medical Oncology, Dana-Farber/Partners Cancer Care, Boston, MA 02215; hHuman Cancer Genetics Program, Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210; and iDepartment of Cancer Biology and Genetics, Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210 Contributed by Albert de la Chapelle, August 28, 2020 (sent for review July 17, 2020; reviewed by Anne Hagemeijer and Stefan Klaus Bohlander) Balanced rearrangements involving the KMT2A gene, located at patterns that include high expression of HOXA genes and thereby 11q23, are among the most frequent chromosome aberrations in contribute to leukemogenesis (14–16).
    [Show full text]
  • Figure S17 Figure S16
    immune responseregulatingcellsurfacereceptorsignalingpathway ventricular cardiacmuscletissuedevelopment t cellactivationinvolvedinimmuneresponse intrinsic apoptoticsignalingpathway single organismalcelladhesion cholesterol biosyntheticprocess myeloid leukocytedifferentiation determination ofadultlifespan response tointerferongamma muscle organmorphogenesis endothelial celldifferentiation brown fatcelldifferentiation mitochondrion organization myoblast differentiation response toprotozoan amino acidtransport leukocyte migration cytokine production t celldifferentiation protein secretion response tovirus angiogenesis Scrt1 Tcf25 Dpf1 Sap30 Ing2 Zfp654 Sp9 Zfp263 Mxi1 Hes6 Zfp395 Rlf Ppp1r13l Snapc1 C030039L03Rik Hif1a Arrb1 Glis3 Rcor2 Hif3a Fbxo21 Dnajc21 Rest Sirt6 Foxj1 Kdm5b Ankzf1 Sos2 Plscr1 Jdp2 Rbbp8 Etv4 Msh5 Mafg Tsc22d3 Nupr1 Ddit3 Cebpg Zfp790 Atf5 Cebpb Atf3 Trim21 Irf9 Irf2 Tbx21 Stat2 Stat1 Zbp1 Irf1 aGOslimPos Ikzf3 Oasl1 Irf7 Trim30a Dhx58 Txk Rorc Rora Nr1d2 Setdb2 Vdr Vax2 Nr1d1 Foxs1 Eno1 Thap3 Nfkbil1 Edf1 Srebf1 Lbr Tead1 Zfp608 Pcx Ift57 Ssbp4 Stat3 Mxd1 Pml Ssh2 Chd7 Maf Cic Bcl3 Prkdc Mbd5 Ppfibp2 Foxp2 Tal2 Mlf1 Bcl6b Zfp827 Ikzf2 Phtf2 Bmyc Plagl2 Nfkb2 Nfkb1 Tox Nrip1 Utf1 Klf3 Plagl1 Nfkbib Spib Nfkbie Akna Rbpj Ncoa3 Id1 Tnp2 Gata3 Gata1 Pparg Id2 Epas1 Zfp280b Commons Pathway Erg GO MSigDB KEGG Hhex WikiPathways SetGene Databases Batf Aff3 Zfp266 gene modules other (hypergeometric TF, from Figure Trim24 Zbtb5 Foxo3 Aebp2 XPodNet -protein-proteininteractionsinthepodocyteexpandedbySTRING Ppp1r10 Dffb Trp53 Enrichment
    [Show full text]
  • Inhibition of HIF1` Signaling: a Grand Slam for MDS Therapy?
    VIEWS IN THE SPOTLIGHT Inhibition of HIF1` Signaling: A Grand Slam for MDS Therapy? Jiahao Chen and Ulrich Steidl Summary: The recent focus on genomics in myelodysplastic syndromes (MDS) has led to important insights and revealed a daunting genetic heterogeneity, which is presenting great challenges for clinical treatment and preci- sion oncology approaches in MDS. Hayashi and colleagues show that multiple mutations frequently found in MDS activate HIF1α signaling, which they also found to be suffi cient to induce overt MDS in mice. Furthermore, both genetic and pharmacologic inhibition of HIF1α suppressed MDS development with only mild effects on normal hematopoiesis, implicating HIF1α signaling as a promising therapeutic target to tackle the heterogeneity of MDS. Cancer Discov; 8(11); 1355–7. ©2018 AACR . See related article by Hayashi et al., p. 1438 (5). Myelodysplastic syndromes (MDS) are a heterogeneous In this issue, Hayashi and colleagues found that target group of hematologic disorders characterized by ineffi cient genes activated by HIF1α signaling were highly expressed in hematopoiesis that manifests as bone marrow (BM) dysplasia a published cohort of 183 patients with MDS compared with and peripheral blood cytopenias, and increased risk of leuke- healthy controls ( 5 ). IHC confi rmed an increased frequency mic transformation ( 1 ). The median survival of patients with of HIF1α-expressing cells in MDS samples at different stages MDS is 4.5 years, with a signifi cantly worse survival of< 1 year (low-, intermediate-, and high-risk)
    [Show full text]
  • Onset of Taste Bud Cell Renewal Starts at Birth and Coincides with a Shift In
    RESEARCH ARTICLE Onset of taste bud cell renewal starts at birth and coincides with a shift in SHH function Erin J Golden1,2, Eric D Larson2,3, Lauren A Shechtman1,2, G Devon Trahan4, Dany Gaillard1,2, Timothy J Fellin1,2, Jennifer K Scott1,2, Kenneth L Jones4, Linda A Barlow1,2* 1Department of Cell & Developmental Biology, University of Colorado Anschutz Medical Campus, Aurora, United States; 2The Rocky Mountain Taste and Smell Center, University of Colorado Anschutz Medical Campus, Aurora, United States; 3Department of Otolaryngology, University of Colorado Anschutz Medical Campus, Aurora, United States; 4Department of Pediatrics, Section of Hematology, Oncology, and Bone Marrow Transplant, University of Colorado Anschutz Medical Campus, Aurora, United States Abstract Embryonic taste bud primordia are specified as taste placodes on the tongue surface and differentiate into the first taste receptor cells (TRCs) at birth. Throughout adult life, TRCs are continually regenerated from epithelial progenitors. Sonic hedgehog (SHH) signaling regulates TRC development and renewal, repressing taste fate embryonically, but promoting TRC differentiation in adults. Here, using mouse models, we show TRC renewal initiates at birth and coincides with onset of SHHs pro-taste function. Using transcriptional profiling to explore molecular regulators of renewal, we identified Foxa1 and Foxa2 as potential SHH target genes in lingual progenitors at birth and show that SHH overexpression in vivo alters FoxA1 and FoxA2 expression relevant to taste buds. We further bioinformatically identify genes relevant to cell adhesion and cell *For correspondence: locomotion likely regulated by FOXA1;FOXA2 and show that expression of these candidates is also LINDA.BARLOW@CUANSCHUTZ. altered by forced SHH expression.
    [Show full text]
  • Supplementary Table 2
    Supplementary Table 2. Differentially Expressed Genes following Sham treatment relative to Untreated Controls Fold Change Accession Name Symbol 3 h 12 h NM_013121 CD28 antigen Cd28 12.82 BG665360 FMS-like tyrosine kinase 1 Flt1 9.63 NM_012701 Adrenergic receptor, beta 1 Adrb1 8.24 0.46 U20796 Nuclear receptor subfamily 1, group D, member 2 Nr1d2 7.22 NM_017116 Calpain 2 Capn2 6.41 BE097282 Guanine nucleotide binding protein, alpha 12 Gna12 6.21 NM_053328 Basic helix-loop-helix domain containing, class B2 Bhlhb2 5.79 NM_053831 Guanylate cyclase 2f Gucy2f 5.71 AW251703 Tumor necrosis factor receptor superfamily, member 12a Tnfrsf12a 5.57 NM_021691 Twist homolog 2 (Drosophila) Twist2 5.42 NM_133550 Fc receptor, IgE, low affinity II, alpha polypeptide Fcer2a 4.93 NM_031120 Signal sequence receptor, gamma Ssr3 4.84 NM_053544 Secreted frizzled-related protein 4 Sfrp4 4.73 NM_053910 Pleckstrin homology, Sec7 and coiled/coil domains 1 Pscd1 4.69 BE113233 Suppressor of cytokine signaling 2 Socs2 4.68 NM_053949 Potassium voltage-gated channel, subfamily H (eag- Kcnh2 4.60 related), member 2 NM_017305 Glutamate cysteine ligase, modifier subunit Gclm 4.59 NM_017309 Protein phospatase 3, regulatory subunit B, alpha Ppp3r1 4.54 isoform,type 1 NM_012765 5-hydroxytryptamine (serotonin) receptor 2C Htr2c 4.46 NM_017218 V-erb-b2 erythroblastic leukemia viral oncogene homolog Erbb3 4.42 3 (avian) AW918369 Zinc finger protein 191 Zfp191 4.38 NM_031034 Guanine nucleotide binding protein, alpha 12 Gna12 4.38 NM_017020 Interleukin 6 receptor Il6r 4.37 AJ002942
    [Show full text]
  • RUNX1 Together with a Compendium of Hematopoietic Regulators, Chromatin Modifiers and Basal Transcr
    Leukemia (2014) 28, 770–778 OPEN & 2014 Macmillan Publishers Limited All rights reserved 0887-6924/14 www.nature.com/leu ORIGINAL ARTICLE CBFB–MYH11/RUNX1 together with a compendium of hematopoietic regulators, chromatin modifiers and basal transcription factors occupies self-renewal genes in inv(16) acute myeloid leukemia A Mandoli1, AA Singh1, PWTC Jansen2, ATJ Wierenga3,4, H Riahi1, G Franci5, K Prange1, S Saeed1, E Vellenga3, M Vermeulen2, HG Stunnenberg1 and JHA Martens1 Different mechanisms for CBFb–MYH11 function in acute myeloid leukemia with inv(16) have been proposed such as tethering of RUNX1 outside the nucleus, interference with transcription factor complex assembly and recruitment of histone deacetylases, all resulting in transcriptional repression of RUNX1 target genes. Here, through genome-wide CBFb–MYH11-binding site analysis and quantitative interaction proteomics, we found that CBFb–MYH11 localizes to RUNX1 occupied promoters, where it interacts with TAL1, FLI1 and TBP-associated factors (TAFs) in the context of the hematopoietic transcription factors ERG, GATA2 and PU.1/SPI1 and the coregulators EP300 and HDAC1. Transcriptional analysis revealed that upon fusion protein knockdown, a small subset of the CBFb–MYH11 target genes show increased expression, confirming a role in transcriptional repression. However, the majority of CBFb–MYH11 target genes, including genes implicated in hematopoietic stem cell self-renewal such as ID1, LMO1 and JAG1, are actively transcribed and repressed upon fusion protein knockdown. Together these results suggest an essential role for CBFb–MYH11 in regulating the expression of genes involved in maintaining a stem cell phenotype. Leukemia (2014) 28, 770–778; doi:10.1038/leu.2013.257 Keywords: CBFb–MYH11; RUNX1; histone acetylation; acute myeloid leukemia; inv(16) INTRODUCTION Heterozygous Cbfb-Myh11 knock-in mice are embryonic lethal, Core-binding transcription factors (CBFs) have roles in stem cell with definitive hematopoiesis blocked at the stem-cell level.
    [Show full text]